NCT03543683View on ClinicalTrials.gov

Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

PHASE2CompletedINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 31, 2023

Study Completion Date

June 1, 2024

Conditions

Non-Small Cell Lung Cancer Stage IIIBNon-small Cell Lung Cancer Stage IVEGFR T790M

Interventions

DRUG

Osimertinib

Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.

DRUG

Aspirin

Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.

Trial Locations (1)

400000

Daping Hospital, Chongqing

All Listed Sponsors

lead

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

NCT03543683 - Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC | Biotech Hunter | Biotech Hunter